onc201
Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism
Clin Cancer Res. 2019 PMID: 30559168
Publications
onc201
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
J Clin Invest. 2018 PMID: 29533922
onc212
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
Oncotarget 2017 PMID: 29137221
onc201
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget
Oncotarget. 2017 PMID: 29108308
imipridones
Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212
Cell Cycle. 2017 PMID: 28489985
onc201
First-in-Human clinical trial of oral ONC201 in patients with refractory solid tumors
Clin Cancer Res. 2017 PMID: 28331050
onc201
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Sci Signal. 2016 PMID: 26884599
onc201
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
Sci Signal. 2016 PMID: 26884600
onc201
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects
Science Translational Medicine 2013, PMID: 23390247